


Stabilis



Carmustine



Noms commerciaux

Becenun	Brésil
Bicnu	Australie, Canada, Chili, Colombie, Espagne, Etats Unis d'Amérique, France, Grande Bretagne, Grèce, Hongrie, Iran, Irlande, Maroc, Mexique, Nouvelle Zélande, Pérou, Roumanie, Suisse, Tunisie
Bodacler	Argentine
Carmubris	Allemagne, Autriche, Iran
Carmustina Grey	Pérou
Carmustina Perulab	Pérou
Carmustine Baxter	Nouvelle Zélande
Carmustine Obvius	Allemagne, Autriche, Belgique, Bulgarie, Croatie, Danemark, Espagne, Finlande, France, Grande Bretagne, Hongrie, Irlande, Islande, Luxembourg, Norvège, Pays bas, Pologne, Portugal, Roumanie, Slovaquie, Slovénie, Suède, Tchèque
Nitrourean	Espagne
Nitrumon	Belgique, Iran, Luxembourg



Stabilité des solutions

		0,96 mg/ml	22°C		3			146
		0,96 mg/ml	4°C		48			146
		0,1 & 0,5 mg/ml	4°C		12			1622
		0,1 > 1 mg/ml	25°C		2			1622
		0,2 mg/ml	23°C		5.5			1501
		0,2 mg/ml	4°C		48			1501
		0,96 mg/ml	4°C		24			146
		0.2 mg/ml	25°C		8			3314
		1 mg/ml	4°C		48			1622

		3,3 mg/ml	2-8°C		24			4762
		0,96 mg/ml	22°C		3			146
		0,96 mg/ml	4°C		48			146
		0,1 mg/ml	25°C		2			1622
		0,1 & 0,5 mg/ml	4°C		48			1622
		0,2 mg/ml	23°C		2.5			1501
		0,2 mg/ml	4°C		48			1501
		0,33 mg/ml	4°C		2			1520
		0,33 & 1,6 mg/ml	22°C		3			1520
		0,5 & 1 mg/ml	25°C		4			1622
		1 mg/ml	4°C		12			1622
		0,2 mg/ml	2-8°C		48			4762
		0,2 mg/ml	22°C		6			4762
		1 mg/ml	2-8°C		48			4762
		1 mg/ml	22°C		8.5			4762
		1 mg/ml	23°C		6			2146

































Facteur influençant la stabilité

				837
				715
				837
				146
	> 30°C			3314
	3,3 < pH < 4,8			837



Compatibilités

			715
			307
			3

	Carmustine : 1.5 mg/ml Aztreonam : 40 mg/ml		99
	Carmustine : 1.5 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Carmustine : 1.5 mg/ml Filgrastim : 30 µg/ml		244
	Carmustine : 1.5 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Carmustine : 1.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Carmustine : 1.5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Carmustine : 1.5 mg/ml Melphalan : 0.1 mg/ml		169
	Carmustine : 1.5 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Carmustine : 1.5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
	Carmustine : 1.5 mg/ml Sargramostim : 10 µg/ml		335
	 Carmustine : 0,1 mg/ml Sodium bicarbonate : 84 mg/ml	 	715
	Carmustine : 1.5 mg/ml Teniposide : 0.1 mg/ml		905
	Carmustine : 1.5 mg/ml Thiotepa : 1 mg/ml		249
	Carmustine : 1.5 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration



Bibliographie



	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.

99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
146	Revue	Hadi-Minaglou-Gonzalvez MF, Gayte-Sorbier A, Airauto CB, Verdier M. Effects of temperature, solution composition, and type of container on the stability and absorption of carmustine. Clin Ther 1992 ; 14: 821-824.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
715	Revue	Colvin M, Hartner J, Summerfield M. Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 1980 ; 37: 677-678.
837	Revue	Fredriksson K, Lundgren P, Landersjo L. Stability of carmustine - kinetics and compatibility during administration. Acta Pharm Suec 1986 ; 23: 115-124.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1501	Revue	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Laboratoire	Etude de stabilité des médicaments en Ecoflac® B Braun 2001

1622	Revue	Favier M, De Casanove F, Coste A, Cherti N, Bressolle F. Stability of carmustine in polyvinyl chloride bags and polyethylene-lined trilayer plastic containers. Am J Health-Syst Pharm 2001 ; 58: 238-241.
2146	Revue	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
3314	Laboratoire	Carmustine (Bicnu®) – Résumé des caractéristiques du produits Bristol Myers Squibb 2011
4762	Revue	Knoll L, Kraemer I, Thiesen J. Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature EJHP 2023 ; 30, 1: 11-16.



Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Heure	 Chlorure de sodium 0,9%
 Glucose 5%	 Solvant spécifique
 Polyéthylène	 Jour
 Polyolefine	 Lumière
 Facteur influençant la stabilité	 Provoque
 Dégradation	 Solvant
 NaHCO ₃	 Polyvinyl chlorure
 Adsorption	 Augmentation
 Augmentation stabilité	 Compatibilités
 Molécule	 Instabilité chimique
 Incompatible	 Dégagement gazeux
 Compatible	 Voie d'administration
 Perfusion intraveineuse	 Bibliographie
 Dictionnaire	